Downregulation of m 6 A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer

Shulei Sun,Qiang Han,Maoli Liang,Qian Zhang,Jing Zhang,Jie Cao
DOI: https://doi.org/10.1111/1759-7714.13667
IF: 3.223
2020-09-21
Thoracic Cancer
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>m<sup>6</sup>A modification affects the pathological progress of many diseases by affecting RNA stability and translocation. YTHDC2, a m<sup>6</sup>A reader, is associated with multiple cancers; however, little is known of its role in non‐small cell lung cancer (NSCLC). </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>The GEPIA, Oncomine and GEO databases were analyzed to assess expression of <i>YTHDC2</i> in NSCLC patients. Quantitative polymerase chain reaction, western blot and immunohistochemistry were used to detect YTHDC2 expression in different NSCLC cell lines (H1299, H460, H292 and A549) and patients. The effects of YTHDC2 on NSCLC cell lines (A549 and H1299) proliferation and migration were employed using CCK8 and transwell assays. The potential target RNAs of YTHDC2 were obtained from the POSTAR database. Functional enrichment analysis of YTHDC2 targeted RNAs was performed using the Metascape database. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>GEPIA, Oncomine and GEO databases showed low expression of <i>YTHDC2</i> in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) patients. YTHDC2 expression was significantly decreased in different NSCLC cell lines and our clinical samples. Moreover, low expression of YTHDC2 was significantly associated with poor differentiation, lymph node metastasis, tumor size and stage. In addition, YTHDC2 could suppress the proliferation and migration ability of A549 and H1299 cell lines. Kaplan‐Meier Plotter database analysis revealed that patients with low level of YTHDC2 had a significantly poor prognosis. Finally, functional enrichment analysis of YTHDC2 targeted RNAs indicated several enriched pathways related to cancer. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>These findings elucidate that YTHDC2 suppresses tumorigenesis in NSCLC, indicating that YTHDC2 may be a promising therapeutic target for NSCLC.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Significant findings of the study</h3><p>This study demonstrated that the downregulation of YTHDC2 promotes tumor progression and predicts poor prognosis in non‐small cell lung cancer (NSCLC).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> What this study adds</h3><p>YTHDC2 might be a promising therapeutic target for non‐small cell lung cancer (NSCLC).</p></section>
oncology,respiratory system
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the expression and biological functions of YTHDC2 in non - small - cell lung cancer (NSCLC), as well as its potential as a therapeutic target. Specifically, by analyzing the expression level of YTHDC2 in NSCLC patients and evaluating its relationship with clinicopathological features, the researchers aim to reveal the role of YTHDC2 in the occurrence and development of NSCLC. In addition, the study also explored the effects of YTHDC2 on the proliferation and migration abilities of NSCLC cells through in vitro experiments, and analyzed the functional enrichment of RNAs targeted by YTHDC2 using bioinformatics methods to further clarify its mechanism in tumorigenesis. The main findings of the study include: - The expression of YTHDC2 in NSCLC tissues and cell lines is significantly decreased. - The low expression of YTHDC2 is significantly associated with poor differentiation, lymph node metastasis, tumor size and stage. - Over - expression of YTHDC2 can inhibit the proliferation and migration abilities of NSCLC cells, while knockdown of YTHDC2 promotes these processes. - Bioinformatics analysis shows that the RNAs targeted by YTHDC2 are mainly involved in nuclear - transcribed mRNA metabolic processes, cadherin binding and translation, etc. - Prognostic analysis indicates that patients with low YTHDC2 expression have a poor prognosis. In conclusion, this study reveals the potential tumor - suppressive role of YTHDC2 in NSCLC, suggesting that it may become a new therapeutic target for NSCLC.